Table 1. Treatment-related mortality,... | American Society of Hematology

Table 1.

Treatment-related mortality, PFS, and OS according to BSA and doxorubicin dose adaptation in patients with DLBCL

	BSA < 2.1 m²	BSA capped ≥ 2.1 m²	BSA uncapped ≥ 2.1 m²	P value
Number (%)	1.232 (89)	119 (8.6)	33 (2.4)
Treatment-related mortality, %	3.9	6.7	6.1	.293*
Median PFS (95% CI)	78.7 (64.6; 91.4)	75.9 (49.7; NA)	57.9 (13.5 ; NA)	.481†
Median OS (95% CI)	106.5 (93.1; 117.9)	113.1 (75.9; NA)	93.1 (32.6 ; NA)	.864†

	BSA < 2.1 m²	BSA capped ≥ 2.1 m²	BSA uncapped ≥ 2.1 m²	P value
Number (%)	1.232 (89)	119 (8.6)	33 (2.4)
Treatment-related mortality, %	3.9	6.7	6.1	.293*
Median PFS (95% CI)	78.7 (64.6; 91.4)	75.9 (49.7; NA)	57.9 (13.5 ; NA)	.481†
Median OS (95% CI)	106.5 (93.1; 117.9)	113.1 (75.9; NA)	93.1 (32.6 ; NA)	.864†

Significance level is P < .05.

NA, not applicable.

χ² test was performed.

Log-rank test was performed. Test was 2 sided.